A study for patients with complicated skin and skin structure infections

Journal of Drugs in Dermatology, March, 2008

Sponsored by: Targanta Therapeutics Corporation. Two Phase III trials to demonstrate the efficacy and safety of oritavancin in the treatment of complicated skin and skin structure infections (cSSSI) have been completed.

Condition                       Intervention       Phase

Staphylococcal Skin Infections  Drug: oritavancin  Phase II
Wounds and Injuries
Abscess
Cellulitis
Streptococcal Infections

Study ID Numbers: TAR-ORI-SD001

ClinicalTrials.gov Identifier: NCT00514527